Becton Dickinson and (BDX) Earnings Date & Reports

BDX delivered Q2 revenue of $4.7 billion, exceeding analyst consensus of $4.67 billion and growing 5.2% as reported (2.6% FXN) from $4.48 billion prior year. Growth was broad-based: Medical Essentials $1.647 billion (+4.7% reported), Connected Care $1.120 billion (+4.9%), BioPharma Systems $590 million (+2.5%), and Interventional $1.357 billion (+7.3%). U.S. revenues rose 5.1% to $2.917 billion; international up 5.5% reported but -1.4% FXN.

GAAP diluted EPS from continuing operations was $(0.13), reflecting $533 million in integration, restructuring, and transaction expenses. Adjusted diluted EPS reached $2.90, beating consensus $2.77 and up 3.9% reported from $2.79, aided by BD Excellence efficiencies. Adjusted operating margin stood at 24.2%, down 110 basis points year-over-year due to tariffs and mix, yet EPS exceeded expectations. Adjusted gross margin was 54.7%.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis.

Market Reaction and Investor Sentiment

BDX shares surged over 5% on May 7, 2026, following the earnings release, with pre-market gains around 3.9-5.4% reflecting enthusiasm for the EPS beat, revenue top, and raised guidance. The positive move came after recent weakness, signaling investor relief on execution post-spin-off and confidence in New BD's margin expansion path despite tariff pressures. Sentiment turned bullish on BD's broad growth and capital returns via ASR and debt reduction.

Forward Outlook and Key Factors to Monitor

BDX reaffirmed fiscal 2026 revenue growth at low single-digit (reported and FXN), supported by first-half breadth and visibility. The adjusted diluted EPS outlook was lifted to $12.52–$12.72, reflecting productivity gains offsetting investments and headwinds like tariffs (160 basis points impact noted in Q2).

Investors should track execution in growth platforms: Interventional (e.g., peripheral vascular), Connected Care (e.g., infusion systems), and Medical Essentials. Margin trends via BD Excellence (operational excellence program) remain pivotal amid product mix shifts and supply costs.

Upcoming catalysts include Q3 results in August, innovation pipeline (e.g., new device launches), and capital allocation—further buybacks or debt paydown post $2B ASR and $2.1B retirement. Monitor medtech demand signals, reimbursement changes, and geopolitical tariff developments, as international FXN softness (-1.4% Q2) could persist. Free cash flow generation ($1.328B operating cash YTD) underpins returns.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations